Sign in
4

Changes in Ownership

Dyne Therapeutics, Inc. Filed Acc 0000950170-25-038750

Chief Commercial Officer sold 143 shares at $12.12 ($1,733)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Friedl-Naderer Johanna · Chief Commercial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-03-13 Sale : show line 1 in the form 10b5-1 −143 $12.12 $1,733 96,057 D
Open-market sales · 143 sh · avg $12.12 · $1,733
Loading xslF345X05/ownership.xml…